PRISM BioLab specializes in innovative drug discovery through its proprietary PepMetics® Technology, which focuses on transforming traditionally "undruggable" targets into viable therapeutic options. This technology utilizes peptide mimetics that are designed to replicate the structural features of α-helices and β-turns found in natural peptides. By employing unique, stable scaffolds, PRISM BioLab's PepMetics molecules can effectively modulate protein-protein interactions (PPIs), which are crucial for many biological processes. The company boasts a comprehensive library of over 20,000 compounds, allowing for extensive screening against challenging targets, thereby enhancing the potential for discovering new drug candidates.

The PepMetics® Technology not only synthesizes compounds akin to small molecules but also retains the functional characteristics of peptides, such as selectivity and affinity for specific protein interactions. This dual capability enables PRISM BioLab to create stable mimetics that maintain the necessary conformational integrity to improve binding affinities. The company has developed a proprietary methodology to analyze and optimize these mimetics, ensuring they closely resemble the natural ligand structures they aim to target. By combining the best attributes of both small molecules and peptides, PRISM BioLab is positioned to advance therapeutic modalities that address significant unmet medical needs.

Japan

PRISM BioLab is committed to maximizing the potential of its PepMetics™ Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.

PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.

PRISM BioLab

Company Details